Logo Logo
Up a level
Export as [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | Date
Number of items: 7.

Journal article

Gluz, O.; Nitz, U.; Liedtke, C.; Christgen, M.; Sotlar, K.; Grischke, E. M.; Forstbauer, H.; Braun, M.; Warm, M.; Hackmann, J.; Uleer, C.; Aktas, B.; Schumacher, C.; Bangemann, N.; Lindner, C.; Kuemmel, S.; Clemens, M.; Potenberg, J.; Staib, P.; Kohls, A.; Pelz, E.; Kates, R. E.; Wuerstlein, R.; Kreipe, H. H.; Harbeck, N. (2016): Comparison of 12 weeks neoadjuvant Nab-paclitaxel combined with carboplatinum vs. gemcitabine in triple negative breast cancer: WSG-ADAPT TN randomized phase II trial. In: Cancer Research, Vol. 76

Wuerstlein, R.; Sotlar, K.; Gluz, O.; Hofmann, D.; Otremba, B.; Schumann, R. von; Witzel, I.; Schindlbeck, C.; Janni, W.; Schem, C.; Bauerfeind, I.; Hasmueller, S.; Tesch, H.; Paulenz, A.; Morel, P.; Cowens, W.; Hornberger, J.; Kates, R. E.; Pelz, E.; Harbeck, N. (2016): Prosigna®(R) results impact on adjuvant decision making in early breast cancer (EBC): Final analysis of the prospective WSG study. In: Cancer Research, Vol. 76

Gluz, O.; Nitz, U.; Liedtke, C.; Christgen, M.; Sotlar, K.; Grischke, E. M.; Forstbauer, H.; Braun, M.; Warm, M.; Hackmann, J.; Uleer, C.; Aktas, B.; Schumacher, C.; Bangemann, N.; Lindner, C.; Kuemmel, S.; Clemens, M.; Potenberg, J.; Staib, P.; Kohls, A.; Pelz, E.; Kates, R. E.; Wuerstlein, R.; Kreipe, H. H.; Harbeck, N. (2016): Comparison of 12 weeks neoadjuvant Nab-paclitaxel combined with carboplatinum vs. gemcitabine in triple negative breast cancer: WSG-ADAPT TN randomized phase II trial. In: Cancer Research, Vol. 76

Gluz, O.; Liedtke, C.; Huober, J.; Peyro-Saint-Paul, H.; Kates, R. E.; Kreipe, H. H.; Hartmann, A.; Pelz, E.; Erber, R.; Mohrmann, S.; Möbus, V.; Augustin, D.; Hoffmann, G.; Thomssen, C.; Jänicke, F.; Kiechle, M.; Wallwiener, D.; Kuhn, W.; Nitz, U.; Harbeck, N. (2016): Comparison of prognostic and predictive impact of genomic or central grade and immunohistochemical subtypes or IHC4 in HR+/HER2-early breast cancer: WSG-AGO EC-Doc Trial. In: Annals of Oncology, Vol. 27, No. 6: pp. 1035-1040

Wuerstlein, R.; Sotlar, K.; Gluz, O.; Hofmann, D.; Otremba, B.; Schumann, R. von; Witzel, I.; Schindlbeck, C.; Janni, W.; Schem, C.; Bauerfeind, I.; Hasmueller, S.; Tesch, H.; Paulenz, A.; Morel, P.; Cowens, W.; Hornberger, A.; Kates, R. E.; Pelz, E.; Harbeck, N. (2016): Prosigna® results impact on adjuvant decision making in early breast cancer (EBC): Final analysis of the prospective WSG study. In: Oncology Research and Treatment, Vol. 39: p. 49

Wuerstlein, R.; Sotlar, K.; Gluz, O.; Otremba, B.; Schumann, R. von; Witzel, I.; Schindlbeck, C.; Janni, W.; Schem, C.; Bauerfeind, I.; Hasmueller, S.; Tesch, H.; Paulenz, A.; Ghali, N.; Orujov, E.; Kates, R. E.; Cowens, W.; Hornberger, J.; Pelz, E.; Harbeck, N. (2016): The West German Study Group Breast Cancer Intrinsic Subtype study: a prospective multicenter decision impact study utilizing the Prosigna assay for adjuvant treatment decision-making in estrogen-receptor-positive, HER2-negative early-stage breast cancer. In: Current Medical Research and Opinion, Vol. 32, No. 7: pp. 1217-1224

Liedtke, C.; Gluz, O.; Nitz, U.; Christgen, M.; Sotlar, K.; Grischke, E.-M.; Forstbauer, H.; Braun, M.; Warm, M.; Hackmann, J.; Uleer, C.; Aktas, B.; Schumacher, C.; Bangemann, N.; Linder, C.; Kümmel, S.; Clemens, M.; Potenberg, J.; Peter, S.; Kohls, A.; Pelz, E.; Kates, R. E.; Würstlein, R.; Kreipe, H.; Harbeck, N. (2016): Comparison of 12 weeks neoadjuvant Nab-Paclitaxel combined with Carboplatinum vs. Gemcitabine in triple negative breast cancer: WSG-ADAPT TN randomized phase II trial. In: Oncology Research and Treatment, Vol. 39: p. 53

This list was generated on Wed May 22 04:52:02 2019 CEST.